Back to News

COVID-19 Resources

The IMPAACT Network has released a response to the COVID-19 pandemic. Read more from IMPAACT Leadership and see guidance from the CDC, DAIDS, EMA, FDA, WHO, and more.


The IMPAACT Network is closely monitoring the ongoing COVID-19 pandemic. The safety and well-being of IMPAACT study participants, community members, clinical research site staff, and laboratory staff are of utmost importance and the highest priority for our Network. We are tracking all updates and heeding recommendations from national and international health organizations, including the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) regarding the disease.

Consistent with guidance from DAIDS, and in consultation with our NIH partners, action steps are as follows (updated 1 September 2020):

  • IMPAACT P1108, IMPAACT P1115, and IMPAACT 2005 were permitted to resume accrual as of 19 July 2020; IMPAACT 2019 was opened to accrual. Sites will need to confirm contingency planning for COVID-19 concerns prior to enrolling into any of these studies.
  • Accrual is only open for studies listed above, once site receives study-specific approvals.
  • For most IMPAACT studies, follow-up of participants continued, and should continue — to the extent possible and in accordance with relevant government and site-specific institutional policies — with emphasis on safety monitoring and ensuring access to treatment regimens for participants living with HIV.
  • Shipments of study specimens to the IMPAACT repositories and designated testing laboratories have resumed

We will continue to provide updates as needed via email and our website. Please stay safe and be well.

Resources and Guidance

Guidance for Re-Opening

General Guidance